Overview: Herpes Simplex Virus 1 and 2 IgM TestIntroduction: The Herpes Simplex Virus 1 and 2 IgM Test detects IgM antibodies to HSV-1 and HSV-2 to diagnose acute infection, causing sores or genital issues. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antiviral therapy, and improving outcomes in serology for patients with suspected acute herpes infections, ensuring timely treatment to reduce severity.
Other Names: HSV 1+2 IgM Assay, Acute Herpes Simplex Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: HSV IgM testing began in the 1980s with herpes research. Combined HSV-1/2 IgM immunoassays improved in the 1990s, enhancing acute infection detection.
Purpose: Diagnoses acute HSV-1 and HSV-2 infections, guides antiviral therapy, and monitors anti-HSV IgM in patients with sores or genital issues.
Test Parameters: 1. HSV 1+2 IgM
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like sores, genital issues, or neurological symptoms, and list medications.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum or CSF within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document sores, genital issues, neurological symptoms, or history of HSV exposure. Include current medications, especially antivirals, and recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy.
Procedural Considerations: Uses an immunoassay to detect anti-HSV-1 and HSV-2 IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for acute herpes diagnosis.
Factors Affecting Result Accuracy: Improper sample handling, early infection, or cross-reactivity between HSV-1 and HSV-2 can affect results. False negatives may occur in very early infection.
Clinical Significance: Positive anti-HSV-1/2 IgM indicates acute HSV infection, prompting antiviral therapy (e.g., acyclovir). Negative results may require repeat testing in early infection.
Specialist Consultation: Consult an infectious disease specialist or dermatologist for result interpretation and treatment planning.
Additional Supporting Tests: HSV-1/2 IgG, HSV PCR, or viral culture to confirm acute HSV infection.
Test Limitations: False negatives may occur in early infection. Cross-reactivity between HSV-1 and HSV-2 may complicate results. Clinical correlation is needed.
References: IDSA Herpes Guidelines, 2023; Clinical Infectious Diseases, Corey L, 2022.
